Tuesday, May 5, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    How NADAC, WAC, and ASP Shape Drug Costs

    How NADAC, WAC, and ASP Shape Drug Costs

    April 20, 2026
    The Hidden Costs Employers Don’t See in Traditional Health Plans

    The Hidden Costs Employers Don’t See in Traditional Health Plans

    March 22, 2026
    The Impact of COVID-19 on Patient Trust

    The Impact of COVID-19 on Patient Trust

    March 3, 2026
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
  • Surveys

    Surveys

    Public Perception of Peptide Regulation and Compounding Practices

    Public Perception of Peptide Regulation and Compounding Practices

    April 19, 2026
    Understanding of Clinical Evidence in Peptide and Hormone Use

    Understanding of Clinical Evidence in Peptide and Hormone Use

    March 30, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    How NADAC, WAC, and ASP Shape Drug Costs

    How NADAC, WAC, and ASP Shape Drug Costs

    April 20, 2026
    The Hidden Costs Employers Don’t See in Traditional Health Plans

    The Hidden Costs Employers Don’t See in Traditional Health Plans

    March 22, 2026
    The Impact of COVID-19 on Patient Trust

    The Impact of COVID-19 on Patient Trust

    March 3, 2026
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
  • Surveys

    Surveys

    Public Perception of Peptide Regulation and Compounding Practices

    Public Perception of Peptide Regulation and Compounding Practices

    April 19, 2026
    Understanding of Clinical Evidence in Peptide and Hormone Use

    Understanding of Clinical Evidence in Peptide and Hormone Use

    March 30, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Uncertainty & Complexity

Twenty-Eight Times Wrong

The NCPDP billing unit mismatches that silently corrupt pharmacy claims — and what they reveal about the infrastructure beneath drug pricing

Kumar Ramalingam by Kumar Ramalingam
May 5, 2026
in Uncertainty & Complexity
0

Somewhere in the processing pipeline between a pharmacy dispensing a drug and a payer adjudicating the claim, there is a conversion step that almost nobody thinks about — until it produces a result that is off by a factor of twenty-eight. The National Council for Prescription Drug Programs maintains the billing unit standard used in pharmacy claims: each (EA), milliliter (ML), or gram (GM). CMS, meanwhile, publishes pricing data using its own unit designations through the Unit of Pricing and Payment System. When these two systems disagree on what constitutes one unit of a given drug, the resulting price comparison is not wrong by a little. It is wrong categorically.

The oral contraceptive example that NCPDP has cited in its own documentation is instructive not because it is unusual but because it is quantifiable. A package billed as one unit under NCPDP conventions and priced as twenty-eight units under CMS conventions produces a twenty-eight-fold discrepancy in per-unit cost. The drug did not become twenty-eight times more expensive. The denominator changed. But downstream systems that compare prices across databases — analytics platforms, reimbursement models, cost-effectiveness analyses — will faithfully propagate the error unless someone builds a crosswalk to catch it.

The problem extends well beyond a single contraceptive example. Any drug where the NCPDP billing unit and the CMS pricing unit diverge is subject to the same class of error. Multi-dose inhalers, ophthalmic solutions, topical creams sold in tubes of varying sizes, combination packs — each presents a mapping challenge that is resolvable in principle but unresolved in practice across the majority of drug pricing databases. The fixes are manual, product-specific, and brittle. A new NDC entry, a reformulation, or a packaging change can invalidate a crosswalk that took weeks to build.

The underlying issue is architectural. NCPDP billing units were designed for pharmacy claims adjudication — they describe how a drug is counted at the point of dispensing. CMS unit types were designed for pricing and reimbursement — they describe how a drug is counted when its cost is published. These two systems were built for different purposes by different organizations at different times, and nobody with sufficient authority has mandated their alignment. The result is not a bug in any single system but a gap between systems that every user of drug pricing data must bridge independently.

Drug pricing analytics platforms attempting cross-dataset reconciliation — comparing WAC, NADAC, and ASP for the same product — inherit this unit mismatch as a first-order problem. WAC is published in the manufacturer’s chosen unit convention. NADAC is published per NCPDP billing unit. ASP uses CMS’s unit definitions. For drugs where all three conventions align — a tablet sold individually, for instance — cross-referencing is straightforward. For drugs where they diverge — solutions, suspensions, multi-dose devices, combination packs — the comparison is meaningless without normalization.

Normalizing to NCPDP billing units as a common denominator is the most frequently proposed solution and the one that introduces the fewest additional assumptions. EA, ML, and GM are physically defined quantities. A milliliter is a milliliter regardless of the dataset. But the mapping from a manufacturer’s packaging unit or CMS’s pricing unit to an NCPDP billing unit is not always unambiguous. A metered-dose inhaler containing 120 actuations of a drug at a specified concentration per actuation — is the billing unit one actuation, one canister, or one gram of the formulation? The answer depends on which pricing database you consult and which convention the publisher applied.

The temptation to solve this computationally — to build automated crosswalks that map every NDC across every pricing dataset to a common unit — underestimates the heterogeneity of the problem. Some mappings are deterministic. Others require clinical judgment about what constitutes a therapeutically meaningful unit. Still others involve ambiguities that even the data publishers cannot resolve without additional context about the product’s labeling, packaging, and intended use.

What makes this a systemic rather than a technical problem is the number of stakeholders who encounter it independently and solve it privately. Every major PBM maintains internal unit crosswalks. Every analytics vendor builds its own mapping tables. Every state Medicaid program that uses NADAC for reimbursement has confronted unit discrepancies with its claims adjudication system. Each of these solutions is proprietary, undisclosed, and potentially inconsistent with every other solution. The industry has collectively spent enormous effort solving the same problem thousands of times, in thousands of slightly different ways, with no mechanism for sharing the results.

A federal unit standard — a single, mandatory convention for publishing drug pricing data that all federal datasets would adopt — would eliminate the root cause. CMS could mandate that all pricing benchmarks it publishes use NCPDP billing units, aligning NADAC, ASP, AMP, and FUL on a common denominator. Manufacturers could be required to report WAC in the same units. The technical lift would be substantial but finite. The political lift would be larger, because unit conventions are not politically salient, and regulators allocate attention to problems that generate headlines. A twenty-eight-fold pricing error on oral contraceptives, however consequential in aggregate, does not compete for regulatory bandwidth with drug price negotiation or insulin caps.

So the problem persists, reproduced daily in pharmacy claims, pricing databases, and analytical models across the country. Every cross-dataset comparison carries an implicit unit assumption. Every assumption carries the possibility of a factor-of-twenty-eight error. The infrastructure beneath drug pricing is not broken in a dramatic way. It is broken in a quiet, pervasive, compounding way — the kind that nobody fixes because everybody has learned to work around it.

ShareTweet
Kumar Ramalingam

Kumar Ramalingam

Kumar Ramalingam is a writer focused on the intersection of science, health, and policy, translating complex issues into accessible insights.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

summary

An in-depth exploration of drug pricing, including key databases like NADAC, WAC, and ASP, and how they influence the pharmaceutical supply chain, policy, and patient advocacy. The episode also introduces MedPricer's innovative pricing intelligence platform, offering valuable insights for healthcare professionals, policymakers, and patients.

Chapters

00:00 Understanding Drug Pricing Dynamics
03:52 Exploring the Drug Pricing Database
10:07 Patient Advocacy and Drug Pricing
13:56 Market Intelligence in Drug Pricing
How NADAC, WAC, and ASP Shape Drug CostsDaily Remedy
YouTube Video X-Tfwy7XKEg
Subscribe

Policy Shift in Peptide Regulation

Clinical Reads

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

by Daily Remedy
April 19, 2026
0

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • Detecting Hospital M&A Synergies Before They’re Announced: A Rate-Based Event Strategy

    Detecting Hospital M&A Synergies Before They’re Announced: A Rate-Based Event Strategy

    0 shares
    Share 0 Tweet 0
  • The ASC Rate Arbitrage: How Ambulatory Surgery Center Growth Looks in Procedure-Level Price Data

    0 shares
    Share 0 Tweet 0
  • Nonlinear Healthcare Models

    0 shares
    Share 0 Tweet 0
  • The Importance of Access Control in the Workplace

    0 shares
    Share 0 Tweet 0
  • Reading Payer Margin Through Hospital Rate Data: A Short-Side Framework for Managed Care Equities

    0 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy